Department of Neurosurgery, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
J Neurooncol. 2010 Dec;100(3):449-57. doi: 10.1007/s11060-010-0201-1. Epub 2010 May 9.
Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) is a multifunctional protein that was first identified in brain astrocytes and that has subsequently been shown to be expressed in different tissues. Despite its many important roles, the clinical significance of PEA-15 expression levels in astrocytic tumors has yet to be properly defined. We studied the PEA-15 expression pattern of 65 patients [diagnosed according to World Health Organization (WHO) criteria] with diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV). PEA-15 expression levels were immunohistochemically measured and categorized as no, low, or high expression. All tumors expressed PEA-15 in our study. Twenty-three (35.4%) and 42 (64.6%) tumors expressed low and high PEA-15 levels, respectively. In grade II astrocytoma (diffuse astrocytoma) and grade III astrocytoma (anaplastic astrocytoma), 100% and 88.9% of patients expressed high PEA-15 levels, respectively, while a smaller number (50%) of patients with grade IV astrocytoma (glioblastoma) expressed high PEA-15 levels. PEA-15 expression level was inversely associated with WHO grade (P = 0.0006). Next, we evaluated prognosis and PEA-15 expression levels in 43 patients with high-grade astrocytomas based on the following parameters: age, gender, WHO grade, surgical resection extent, MIB-1 labeling index (LI), and PEA-15 expression level. Multivariable analyses revealed that high PEA-15 expression level displayed a significant correlation with longer overall survival (OS) in high-grade astrocytomas (P = 0.0024). Patients with total resection survived significantly longer (P = 0.0044) than those with lower resection extent, while patients with MIB-1 labeling index ≤25% indicated significant (P = 0.0434) correlation with OS as well. In conclusion, PEA-15 expression level was inversely associated with WHO grade and may serve as an important prognostic factor for high-grade astrocytomas.
富含星形胶质细胞的磷酸蛋白 15kDa(PEA-15)是一种多功能蛋白,最初在脑星形胶质细胞中被发现,随后在不同的组织中被证明有表达。尽管 PEA-15 具有许多重要的作用,但其在星形细胞瘤中的表达水平的临床意义尚未得到明确界定。我们研究了 65 例弥漫性星形细胞瘤(WHO 二级)、间变性星形细胞瘤(三级)和胶质母细胞瘤(四级)患者的 PEA-15 表达模式[根据世界卫生组织(WHO)标准诊断]。通过免疫组织化学方法测量 PEA-15 的表达水平,并将其分为无表达、低表达和高表达。在我们的研究中,所有肿瘤均表达 PEA-15。23 例(35.4%)和 42 例(64.6%)肿瘤分别表达低水平和高水平 PEA-15。在二级星形细胞瘤(弥漫性星形细胞瘤)和三级星形细胞瘤(间变性星形细胞瘤)中,分别有 100%和 88.9%的患者表达高水平 PEA-15,而四级星形细胞瘤(胶质母细胞瘤)中较少的患者(50%)表达高水平 PEA-15。PEA-15 的表达水平与 WHO 分级呈负相关(P = 0.0006)。接下来,我们根据以下参数评估了 43 例高级别星形细胞瘤患者的预后和 PEA-15 表达水平:年龄、性别、WHO 分级、手术切除范围、MIB-1 标记指数(LI)和 PEA-15 表达水平。多变量分析显示,高水平 PEA-15 表达与高级别星形细胞瘤的总生存期(OS)延长显著相关(P = 0.0024)。完全切除的患者生存期明显延长(P = 0.0044),而切除范围较低的患者生存期明显缩短,而 MIB-1 标记指数≤25%的患者与 OS 也有显著相关性(P = 0.0434)。总之,PEA-15 的表达水平与 WHO 分级呈负相关,可能是高级别星形细胞瘤的一个重要预后因素。